Aranda Richard 4

Accession 0001728117-23-000057

CIK 0001728117other

View on SEC.gov Company Profile

Filed

May 8, 8:00 PM ET

Accepted

May 9, 4:22 PM ET

Size

31.4 KB

Accession

0001728117-23-000057

Insider Transaction Report

Form 4

Period: 2023-05-05

Gossamer Bio, Inc.GOSS

Aranda Richard

Chief Medical Officer

Transactions

Award
Stock Option (Right to Buy)
2023-05-05+9,167→ 9,167 total
Exercise: $1.36Exp: 2029-12-23→ Common Stock (9,167 underlying)
Award
Stock Option (Right to Buy)
2023-05-05+20,000→ 20,000 total
Exercise: $1.36Exp: 2031-06-21→ Common Stock (20,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-05-05−45,000→ 0 total
Exercise: $22.10Exp: 2029-03-25→ Common Stock (45,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-05-05−60,000→ 0 total
Exercise: $9.79Exp: 2031-02-25→ Common Stock (60,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-05-05−30,000→ 0 total
Exercise: $8.47Exp: 2031-06-21→ Common Stock (30,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-05-05−190,000→ 0 total
Exercise: $11.94Exp: 2032-01-05→ Common Stock (190,000 underlying)
Award
Stock Option (Right to Buy)
2023-05-05+30,000→ 30,000 total
Exercise: $1.36Exp: 2029-03-25→ Common Stock (30,000 underlying)
Award
Stock Option (Right to Buy)
2023-05-05+22,784→ 22,784 total
Exercise: $1.36Exp: 2030-02-14→ Common Stock (22,784 underlying)
Award
Stock Option (Right to Buy)
2023-05-05+126,667→ 126,667 total
Exercise: $1.36Exp: 2032-01-05→ Common Stock (126,667 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-05-05−13,750→ 0 total
Exercise: $16.40Exp: 2029-12-23→ Common Stock (13,750 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-05-05−34,175→ 0 total
Exercise: $14.55Exp: 2030-02-14→ Common Stock (34,175 underlying)
Award
Stock Option (Right to Buy)
2023-05-05+40,000→ 40,000 total
Exercise: $1.36Exp: 2031-02-25→ Common Stock (40,000 underlying)

Footnotes (13)

[F1]The shares subject to the option are fully vested.
[F10]On May 5, 2023, the Issuer canceled an option granted on June 21, 2021. In exchange for the canceled option, the reporting person received 20,000 options to purchase common stock having a lower exercise price with the same vesting terms.
[F11]One-third of the total number of shares subject to the option vested on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
[F12]On May 5, 2023, the Issuer canceled an option granted on January 6, 2022. In exchange for the canceled option, the reporting person received 126,667 options to purchase common stock having a lower exercise price with the same vesting terms.
[F13]The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.
[F2]On May 5, 2023, the Issuer canceled an option granted on March 25, 2019. In exchange for the canceled option, the reporting person received 30,000 options to purchase common stock having a lower exercise price with the same vesting terms.
[F3]25% of the total number of shares subject to the option vested on December 23, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
[F4]On May 5, 2023, the Issuer canceled an option granted on December 23, 2019. In exchange for the canceled option, the reporting person received 9,167 options to purchase common stock having a lower exercise price with the same vesting terms.
[F5]25% of the total number of shares subject to the option vested on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
[F6]On May 5, 2023, the Issuer canceled an option granted on February 14, 2020. In exchange for the canceled option, the reporting person received 22,784 options to purchase common stock having a lower exercise price with the same vesting terms.
[F7]25% of the total number of shares subject to the option vested on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
[F8]On May 5, 2023, the Issuer canceled an option granted on February 25, 2021. In exchange for the canceled option, the reporting person received 40,000 options to purchase common stock having a lower exercise price with the same vesting terms.
[F9]25% of the total number of shares subject to the option vested on June 21, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Documents

1 file

4
wf-form4_168366370450924.xmlPrimary
FORM 4

Issuer

Gossamer Bio, Inc.

CIK 0001728117

→

Entity typeother

Related Parties

filerCIK 0001867872

Filing Metadata

Form type: 4
Filed: May 8, 8:00 PM ET
Accepted: May 9, 4:22 PM ET
Size: 31.4 KB

View on SEC.gov